Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure
(NASDAQ: PGEN) Delayed: 5.36 -0.02 (0.37%)
Previous Close $5.38    52 Week High $ 
Open $5.29    52 Week Low $ 
Day High $5.59    P/E N/A 
Day Low $5.27    EPS $ 
Volume 5,246,934